408 related articles for article (PubMed ID: 26027763)
1. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
[TBL] [Abstract][Full Text] [Related]
2. Integrin β4 and vinculin contained in exosomes are potential markers for progression of prostate cancer associated with taxane-resistance.
Kawakami K; Fujita Y; Kato T; Mizutani K; Kameyama K; Tsumoto H; Miura Y; Deguchi T; Ito M
Int J Oncol; 2015 Jul; 47(1):384-90. PubMed ID: 25997717
[TBL] [Abstract][Full Text] [Related]
3. CD44v8-10 mRNA contained in serum exosomes as a diagnostic marker for docetaxel resistance in prostate cancer patients.
Kato T; Mizutani K; Kawakami K; Fujita Y; Ehara H; Ito M
Heliyon; 2020 Jul; 6(7):e04138. PubMed ID: 32642575
[TBL] [Abstract][Full Text] [Related]
4. EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).
Hour TC; Chung SD; Kang WY; Lin YC; Chuang SJ; Huang AM; Wu WJ; Huang SP; Huang CY; Pu YS
Arch Toxicol; 2015 Apr; 89(4):591-605. PubMed ID: 24888374
[TBL] [Abstract][Full Text] [Related]
5. ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro.
Oprea-Lager DE; Bijnsdorp IV; VAN Moorselaar RJ; VAN DEN Eertwegh AJ; Hoekstra OS; Geldof AA
Anticancer Res; 2013 Feb; 33(2):387-91. PubMed ID: 23393328
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.
Kharaziha P; Chioureas D; Rutishauser D; Baltatzis G; Lennartsson L; Fonseca P; Azimi A; Hultenby K; Zubarev R; Ullén A; Yachnin J; Nilsson S; Panaretakis T
Oncotarget; 2015 Aug; 6(25):21740-54. PubMed ID: 25844599
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity.
Saupe M; Rauschenberger L; Preuß M; Oswald S; Fussek S; Zimmermann U; Walther R; Knabbe C; Burchardt M; Stope MB
World J Urol; 2015 Oct; 33(10):1481-6. PubMed ID: 25544376
[TBL] [Abstract][Full Text] [Related]
8. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
Paller CJ; Antonarakis ES
Drug Des Devel Ther; 2011 Mar; 5():117-24. PubMed ID: 21448449
[TBL] [Abstract][Full Text] [Related]
9. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
10. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
[TBL] [Abstract][Full Text] [Related]
11. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
Petrylak DP
Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
[TBL] [Abstract][Full Text] [Related]
12. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
[TBL] [Abstract][Full Text] [Related]
13. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
Corcoran C; Rani S; O'Driscoll L
Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
[TBL] [Abstract][Full Text] [Related]
14. Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein.
Duran GE; Derdau V; Weitz D; Philippe N; Blankenstein J; Atzrodt J; Sémiond D; Gianolio DA; Macé S; Sikic BI
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1095-1103. PubMed ID: 29675746
[TBL] [Abstract][Full Text] [Related]
15. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
[TBL] [Abstract][Full Text] [Related]
16. Identification of docetaxel resistance genes in castration-resistant prostate cancer.
Marín-Aguilera M; Codony-Servat J; Kalko SG; Fernández PL; Bermudo R; Buxo E; Ribal MJ; Gascón P; Mellado B
Mol Cancer Ther; 2012 Feb; 11(2):329-39. PubMed ID: 22027694
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
Armstrong CM; Liu C; Lou W; Lombard AP; Evans CP; Gao AC
Prostate; 2017 Jun; 77(9):1020-1028. PubMed ID: 28485104
[TBL] [Abstract][Full Text] [Related]
18. Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
Watanabe H; Kawakami A; Sato R; Watanabe K; Matsushita Y; Miyake H
Anticancer Res; 2021 Aug; 41(8):3753-3758. PubMed ID: 34281834
[TBL] [Abstract][Full Text] [Related]
19. Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.
Codony-Servat J; Marín-Aguilera M; Visa L; García-Albéniz X; Pineda E; Fernández PL; Filella X; Gascón P; Mellado B
Prostate; 2013 Apr; 73(5):512-21. PubMed ID: 23038213
[TBL] [Abstract][Full Text] [Related]
20. Effects of Cabazitaxel in Renal Cell Carcinoma Cell Lines.
Mizutani K; Tomoda M; Ohno Y; Hayashi H; Fujita Y; Kawakami K; Kameyama K; Kato T; Sugiyama T; Itoh Y; Ito M; Deguchi T
Anticancer Res; 2015 Dec; 35(12):6671-7. PubMed ID: 26637883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]